$BIOLQ
BIOLASE, INC

2023 Q2 Form 10-Q Financial Statement

#000095017023021323 Filed on May 11, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $14.29M $10.47M $10.17M
YoY Change 16.76% 2.96% 25.26%
Cost Of Revenue $8.168M $7.130M $5.437M
YoY Change 15.14% 31.14% 1.15%
Gross Profit $6.118M $3.337M $4.729M
YoY Change 19.0% -29.44% 72.53%
Gross Profit Margin 42.83% 31.88% 46.52%
Selling, General & Admin $8.546M $7.081M $7.391M
YoY Change 0.04% -4.19% 6.95%
% of Gross Profit 139.69% 212.2% 156.29%
Research & Development $1.444M $1.547M $1.544M
YoY Change -12.64% 0.19% -14.36%
% of Gross Profit 23.6% 46.36% 32.65%
Depreciation & Amortization $1.424M $149.0K $117.0K
YoY Change 995.38% 27.35% 37.65%
% of Gross Profit 23.28% 4.47% 2.47%
Operating Expenses $9.990M $8.628M $8.935M
YoY Change -2.02% -3.44% 1.5%
Operating Profit -$3.872M -$5.291M -$4.206M
YoY Change -23.4% 25.8% -30.62%
Interest Expense -$583.0K -$577.0K -$433.0K
YoY Change 35.58% 33.26% -24.7%
% of Operating Profit
Other Income/Expense, Net -$965.0K -$557.0K -$553.0K
YoY Change 81.05% 0.72% -29.01%
Pretax Income -$4.837M -$5.848M -$4.759M
YoY Change -13.44% 22.88% -30.43%
Income Tax $31.00K $1.000K $17.00K
% Of Pretax Income
Net Earnings -$4.868M -$5.800M -$4.776M
YoY Change -13.24% 21.44% -30.79%
Net Earnings / Revenue -34.08% -55.41% -46.98%
Basic Earnings Per Share -$8.93 -$0.18 -$0.81
Diluted Earnings Per Share -$8.93 -$0.18 -$775.5K
COMMON SHARES
Basic Shares Outstanding 27.73M 26.33B 154.3M
Diluted Shares Outstanding 545.0K 32.81M 6.159M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.930M $6.532M $21.61M
YoY Change -64.55% -69.77% -47.1%
Cash & Equivalents $6.900M $6.500M $21.60M
Short-Term Investments
Other Short-Term Assets $2.170M $2.499M $2.386M
YoY Change 5.14% 4.74% 35.57%
Inventory $13.33M $17.78M $14.61M
Prepaid Expenses
Receivables $5.700M $5.200M $5.200M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $28.15M $31.96M $43.78M
YoY Change -36.42% -26.99% -24.18%
LONG-TERM ASSETS
Property, Plant & Equipment $6.371M $4.719M $1.244M
YoY Change 364.02% 279.34% 79.51%
Goodwill $2.900M $2.900M $2.900M
YoY Change 0.0% 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $279.0K $257.0K $231.0K
YoY Change 15.77% 11.26% 2.21%
Total Long-Term Assets $11.49M $9.980M $6.459M
YoY Change 74.37% 54.51% 12.62%
TOTAL ASSETS
Total Short-Term Assets $28.15M $31.96M $43.78M
Total Long-Term Assets $11.49M $9.980M $6.459M
Total Assets $39.63M $41.94M $50.24M
YoY Change -22.07% -16.52% -20.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.314M $7.540M $4.643M
YoY Change 27.27% 62.4% 51.14%
Accrued Expenses $7.734M $7.977M $6.027M
YoY Change 19.02% 32.35% 904.5%
Deferred Revenue $2.236M $2.082M $2.442M
YoY Change -10.27% -14.74% 24.53%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $1.400M $0.00
YoY Change
Total Short-Term Liabilities $18.38M $19.00M $13.11M
YoY Change 31.78% 44.9% 16.34%
LONG-TERM LIABILITIES
Long-Term Debt $11.90M $12.50M $13.67M
YoY Change -6.5% -8.56% -16.13%
Other Long-Term Liabilities $79.00K $78.00K $387.0K
YoY Change -62.38% -79.84% 402.6%
Total Long-Term Liabilities $11.98M $12.57M $14.05M
YoY Change -7.41% -10.52% -14.16%
TOTAL LIABILITIES
Total Short-Term Liabilities $18.38M $19.00M $13.11M
Total Long-Term Liabilities $11.98M $12.57M $14.05M
Total Liabilities $32.29M $33.79M $29.64M
YoY Change 10.44% 13.98% -1.09%
SHAREHOLDERS EQUITY
Retained Earnings -$306.9M -$302.0M -$272.3M
YoY Change 10.42% 10.91% 5.43%
Common Stock $314.1M $310.8M $293.6M
YoY Change 4.56% 5.88% 0.44%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.621M $8.158M $20.60M
YoY Change
Total Liabilities & Shareholders Equity $39.63M $41.94M $50.24M
YoY Change -22.07% -16.52% -20.86%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$4.868M -$5.800M -$4.776M
YoY Change -13.24% 21.44% -30.79%
Depreciation, Depletion And Amortization $1.424M $149.0K $117.0K
YoY Change 995.38% 27.35% 37.65%
Cash From Operating Activities -$3.562M -$5.658M -$8.021M
YoY Change -46.13% -29.46% 23.42%
INVESTING ACTIVITIES
Capital Expenditures $357.0K $587.0K $304.0K
YoY Change -230.29% 93.09% 3700.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$357.0K -$587.0K -$304.0K
YoY Change 30.29% 93.09% 3700.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $4.800M
YoY Change -63.91%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.276M 8.517M 0.000
YoY Change -11.82% -100.0%
NET CHANGE
Cash From Operating Activities -3.562M -5.658M -8.021M
Cash From Investing Activities -357.0K -587.0K -304.0K
Cash From Financing Activities 4.276M 8.517M 0.000
Net Change In Cash 357.0K 2.351M -8.366M
YoY Change -117.53% -128.1% -136.11%
FREE CASH FLOW
Cash From Operating Activities -$3.562M -$5.658M -$8.021M
Capital Expenditures $357.0K $587.0K $304.0K
Free Cash Flow -$3.919M -$6.245M -$8.325M
YoY Change -38.17% -24.98% 27.94%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000811240
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-36385
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
BIOLASE, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0442441
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
27042 Towne Centre Drive
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 270
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5841000
CY2023Q1 us-gaap Inventory Net
InventoryNet
17775000
CY2022Q4 us-gaap Inventory Net
InventoryNet
15884000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2499000
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Lake Forest
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92610
CY2023Q1 dei City Area Code
CityAreaCode
949
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
361-1200
CY2023Q1 dei Security12b Title
Security12bTitle
Common stock, par value $0.001 per share
CY2023Q1 dei Trading Symbol
TradingSymbol
BIOL
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
27734142
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6532000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4181000
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2124000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2164000
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5158000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
301782000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-653000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3053000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
31964000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
28959000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4719000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4278000
CY2023Q1 us-gaap Goodwill
Goodwill
2926000
CY2022Q4 us-gaap Goodwill
Goodwill
2926000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2078000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1768000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
257000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
255000
CY2023Q1 us-gaap Assets
Assets
41944000
CY2022Q4 us-gaap Assets
Assets
38186000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
7540000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5786000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7977000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9210000
CY2023Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2082000
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2111000
CY2023Q1 us-gaap Mediumterm Notes Current
MediumtermNotesCurrent
1400000
CY2022Q4 us-gaap Mediumterm Notes Current
MediumtermNotesCurrent
700000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
18999000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17807000
CY2023Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
355000
CY2022Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
418000
CY2023Q1 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
426000
CY2022Q4 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
360000
CY2023Q1 us-gaap Mediumterm Notes Noncurrent
MediumtermNotesNoncurrent
12496000
CY2022Q4 us-gaap Mediumterm Notes Noncurrent
MediumtermNotesNoncurrent
13091000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1432000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1259000
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
78000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
362000
CY2023Q1 us-gaap Liabilities
Liabilities
33786000
CY2022Q4 us-gaap Liabilities
Liabilities
33297000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
180000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
180000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26329000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7723000
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26327000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7721000
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
26000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
8000
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
310802000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-733000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-302017000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-296168000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
8158000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
4889000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
41944000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
38186000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10467000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10166000
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
7130000
CY2022Q1 us-gaap Cost Of Revenue
CostOfRevenue
5437000
CY2023Q1 us-gaap Gross Profit
GrossProfit
3337000
CY2022Q1 us-gaap Gross Profit
GrossProfit
4729000
CY2023Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4622000
CY2022Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4814000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2459000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2577000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1547000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1544000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
8628000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
8935000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5291000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4206000
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
20000
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-120000
CY2023Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-577000
CY2022Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-433000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-557000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-553000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5848000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4759000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
17000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5849000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-4776000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
80000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-41000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5769000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4817000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5849000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-4776000
CY2023Q1 biol Deemed Dividend On Convertible Preferred Stock
DeemedDividendOnConvertiblePreferredStock
0
CY2022Q1 biol Deemed Dividend On Convertible Preferred Stock
DeemedDividendOnConvertiblePreferredStock
217000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5849000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4993000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.81
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.81
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32806000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32806000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6159000
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6159000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
4889000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
8503000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
521000
CY2023Q1 biol Stock Issued During Period Value Common Stock Warrants Exercised
StockIssuedDuringPeriodValueCommonStockWarrantsExercised
14000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5849000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
80000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
8158000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
25208000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
209000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-4776000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-41000
CY2022Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
20600000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-5849000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-4776000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
149000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
117000
CY2023Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-17000
CY2022Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
84000
CY2023Q1 biol Provision For Sales Returns
ProvisionForSalesReturns
0
CY2022Q1 biol Provision For Sales Returns
ProvisionForSalesReturns
60000
CY2023Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
107000
CY2022Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
67000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
691000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
209000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-700000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1085000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1890000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1682000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-240000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
186000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
303000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-986000
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-92000
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
157000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5658000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8021000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
587000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
304000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-587000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-304000
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8503000
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2023Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
14000
CY2022Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8517000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
CY2023Q1 biol Effect Of Exchange Rate Changes
EffectOfExchangeRateChanges
79000
CY2022Q1 biol Effect Of Exchange Rate Changes
EffectOfExchangeRateChanges
-41000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2351000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8366000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4181000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30175000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6532000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21809000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
470000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
377000
CY2023Q1 us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
2000
CY2022Q1 us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
10000
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-14000
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
26000
CY2023Q1 biol Cash Paid For Operating Leases
CashPaidForOperatingLeases
68000
CY2022Q1 biol Cash Paid For Operating Leases
CashPaidForOperatingLeases
66000
CY2023Q1 biol Non Cash Right Of Use Assets Obtained In Exchange For Lease Obligation
NonCashRightOfUseAssetsObtainedInExchangeForLeaseObligation
464000
CY2022Q1 biol Non Cash Right Of Use Assets Obtained In Exchange For Lease Obligation
NonCashRightOfUseAssetsObtainedInExchangeForLeaseObligation
444000
CY2023Q1 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
0
CY2022Q1 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
217000
CY2023Q1 biol Working Capital
WorkingCapital
13000000.0
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6500000
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5200000
CY2022Q4 biol Working Capital
WorkingCapital
11200000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4200000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5800000
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8500000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5800000
CY2023Q1 biol Capital Expenditures
CapitalExpenditures
600
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of these consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect amounts reported in the consolidated financial statements and the accompanying notes. Significant estimates in these consolidated financial statements include allowances on accounts receivable, inventory, and deferred taxes, as well as estimates for accrued warranty expenses, goodwill and the ability of goodwill to be realized, revenue deferrals, effects of stock-based compensation and warrants, contingent liabilities, and the provision or benefit for income taxes. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may differ materially from those estimates.</span></p>
CY2023Q1 biol Revenue From Products And Services Transferred To Customers Percentage
RevenueFromProductsAndServicesTransferredToCustomersPercentage
0.89
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concentration of Credit Risk, Interest Rate Risk and Foreign Currency Exchange Rate</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments which potentially expose the Company to a concentration of credit risk consist principally of cash and cash equivalents, restricted cash, and trade accounts receivable. The Company maintains its cash and cash equivalents and restricted cash with established commercial banks. At times, balances may exceed federally insured limits. To minimize the risk associated with trade accounts receivable, management performs ongoing credit evaluations of customers’ financial condition and maintains relationships with the Company’s customers that allow management to monitor current changes in business operations so the Company can respond as needed. The Company does not, generally, require customers to provide collateral before it sells them its products. However, the Company has required certain distributors to make prepayments for significant purchases of its products.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Substantially all of the Company’s revenue is denominated in U.S. dollars, including sales to international distributors. Only a small portion of its revenue and expenses is denominated in foreign currencies, principally the Euro and Indian Rupee. The Company’s foreign currency expenditures primarily consist of the cost of maintaining offices, consulting services, and employee-related costs. During the three months ended March 31, 2023 and 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively, the Company did not enter into any hedging contracts. Future fluctuations in the value of the U.S. dollar may affect the price competitiveness of the Company’s products outside the U.S.</span></p>
CY2022Q1 biol Revenue From Products And Services Transferred To Customers Percentage
RevenueFromProductsAndServicesTransferredToCustomersPercentage
0.89
CY2023Q1 biol Revenue From Services Transferred To Customers Over Time Percentage
RevenueFromServicesTransferredToCustomersOverTimePercentage
0.11
CY2022Q1 biol Revenue From Services Transferred To Customers Over Time Percentage
RevenueFromServicesTransferredToCustomersOverTimePercentage
0.11
CY2023Q1 biol Contract With Customer Liability In Undelivered Elements
ContractWithCustomerLiabilityInUndeliveredElements
400000
CY2022Q4 biol Contract With Customer Liability In Undelivered Elements
ContractWithCustomerLiabilityInUndeliveredElements
400000
CY2023Q1 biol Contract With Customer Liability In Undelivered Elements
ContractWithCustomerLiabilityInUndeliveredElements
376000
CY2022Q4 biol Contract With Customer Liability In Undelivered Elements
ContractWithCustomerLiabilityInUndeliveredElements
447000
CY2023Q1 biol Contract With Customer Liability In Extended Warranty Contracts
ContractWithCustomerLiabilityInExtendedWarrantyContracts
2061000
CY2022Q4 biol Contract With Customer Liability In Extended Warranty Contracts
ContractWithCustomerLiabilityInExtendedWarrantyContracts
2082000
CY2023Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2437000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2529000
CY2023Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
355000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
418000
CY2023Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2082000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2111000
CY2023Q1 biol Contract With Customer Liability Revenue Recognized Undelivered Elements
ContractWithCustomerLiabilityRevenueRecognizedUndeliveredElements
200000
CY2022Q1 biol Contract With Customer Liability Revenue Recognized Undelivered Elements
ContractWithCustomerLiabilityRevenueRecognizedUndeliveredElements
200000
CY2023Q1 biol Contract With Customer Liability Revenue Recognized Extended Warranty
ContractWithCustomerLiabilityRevenueRecognizedExtendedWarranty
700000
CY2022Q1 biol Contract With Customer Liability Revenue Recognized Extended Warranty
ContractWithCustomerLiabilityRevenueRecognizedExtendedWarranty
200000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10467000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10166000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
237.92
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
52000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
74.20
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y6M
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10467000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10166000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10467000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10166000
CY2023Q1 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
1000000
CY2023Q1 biol Allocated Share Based Compensation Expense Credit
AllocatedShareBasedCompensationExpenseCredit
700000
CY2022Q1 biol Allocated Share Based Compensation Expense Credit
AllocatedShareBasedCompensationExpenseCredit
200000
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1000000.0
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
800000
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P0Y10M24D
CY2023Q1 us-gaap Deferred Compensation Share Based Arrangements Liability Current
DeferredCompensationShareBasedArrangementsLiabilityCurrent
200000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
691000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
209000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
52000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
74.95
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y9M18D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
50000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
75.98
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y4M24D
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2023Q1 biol Share Based Compensation Arrangement By Share Based Payment Award Vested Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedOptionsExpirationsInPeriod
0
CY2023Q1 biol Share Based Compensation Arrangement By Share Based Payment Award Vested Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedOptionsExpirationsInPeriodWeightedAverageExercisePrice
0
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
6000
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
14000
CY2023Q1 biol Offering Of Common Stock
OfferingOfCommonStock
2700000
CY2022Q1 biol Offering Of Common Stock
OfferingOfCommonStock
900000
CY2023Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
7833000
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
6697000
CY2023Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
2141000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1871000
CY2023Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
7801000
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
7316000
CY2023Q1 us-gaap Inventory Net
InventoryNet
17775000
CY2022Q4 us-gaap Inventory Net
InventoryNet
15884000
CY2023Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
2100000
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
2200000
CY2023Q1 biol Property Plant And Equipment Gross Excluding Land
PropertyPlantAndEquipmentGrossExcludingLand
13252000
CY2022Q4 biol Property Plant And Equipment Gross Excluding Land
PropertyPlantAndEquipmentGrossExcludingLand
12661000
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8690000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8538000
CY2023Q1 biol Property Plant And Equipment Net Excluding Land
PropertyPlantAndEquipmentNetExcludingLand
4562000
CY2022Q4 biol Property Plant And Equipment Net Excluding Land
PropertyPlantAndEquipmentNetExcludingLand
4123000
CY2023Q1 us-gaap Land
Land
157000
CY2022Q4 us-gaap Land
Land
155000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4719000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4278000
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
100000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
100000
CY2023Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2023Q1 biol Discount Rate For Fair Value Level3
DiscountRateForFairValueLevel3
0.157
CY2023Q1 us-gaap Goodwill
Goodwill
2900000
CY2022Q4 us-gaap Goodwill
Goodwill
2900000
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3911000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4674000
CY2023Q1 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1429000
CY2022Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1293000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
771000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
638000
CY2023Q1 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
329000
CY2022Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
490000
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
315000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
591000
CY2023Q1 us-gaap Taxes Payable Current
TaxesPayableCurrent
314000
CY2022Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
432000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
908000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1092000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7977000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9210000
CY2022Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1653000
CY2021Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1086000
CY2023Q1 us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
1158000
CY2022Q1 us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
551000
CY2023Q1 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
956000
CY2022Q1 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
499000
CY2023Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1855000
CY2022Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1138000
CY2023Q1 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
426000
CY2022Q1 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
512000
CY2023Q1 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1429000
CY2022Q1 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
626000
CY2023Q1 us-gaap Long Term Debt
LongTermDebt
13896000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
13791000
CY2023Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
1400000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
700000
CY2023Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
12496000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
13091000
CY2023Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
600000
CY2022Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
400000
CY2023Q1 us-gaap Debt Weighted Average Interest Rate
DebtWeightedAverageInterestRate
0.1384
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
700000
CY2023Q1 biol Long Term Debt Maturities Repayments Of Interest Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfInterestRemainderOfFiscalYear
1393000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
2800000
CY2023Q1 biol Long Term Debt Maturities Repayments Of Interest In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfInterestInNextTwelveMonths
1623000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
11150000
CY2023Q1 biol Long Term Debt Maturities Repayments Of Interest In Year Two
LongTermDebtMaturitiesRepaymentsOfInterestInYearTwo
712000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
0
CY2023Q1 biol Long Term Debt Maturities Repayments Of Interest In Year Three
LongTermDebtMaturitiesRepaymentsOfInterestInYearThree
9000
CY2023Q1 biol Long Term Debt Maturities Repayments Of Principal After Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour
150000
CY2023Q1 biol Long Term Debt Maturities Repayments Of Interest In Year After Four
LongTermDebtMaturitiesRepaymentsOfInterestInYearAfterFour
89000
CY2023Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
14800000
CY2023Q1 biol Long Term Debt Maturities Repayments Of Interest
LongTermDebtMaturitiesRepaymentsOfInterest
3826000
CY2023Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P1Y
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
68000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
66000
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
464000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
444000
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y6M
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y4M24D
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.123
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.123
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
994000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
984000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
608000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
0
CY2023Q1 biol Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
0
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2586000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
383000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
2203000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
771000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1432000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
2203000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2100000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
2200000
CY2023Q1 us-gaap Payments For Rent
PaymentsForRent
300000
CY2022Q1 us-gaap Payments For Rent
PaymentsForRent
200000
CY2023Q1 biol Future Minimum Payments Remainder Of Fiscal Year
FutureMinimumPaymentsRemainderOfFiscalYear
734000
CY2023Q1 biol Future Minimum Payments Due In One Year
FutureMinimumPaymentsDueInOneYear
1042000
CY2023Q1 biol Future Minimum Payments Due In Two Years
FutureMinimumPaymentsDueInTwoYears
810000
CY2023Q1 biol Future Minimum Payments Due In Three Years
FutureMinimumPaymentsDueInThreeYears
0
CY2023Q1 biol Future Minimum Payments Due Thereafter
FutureMinimumPaymentsDueThereafter
0
CY2023Q1 biol Future Minimum Payments Due
FutureMinimumPaymentsDue
2586000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
383000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
2203000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10467000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10166000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4719000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4278000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10467000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10166000
CY2023Q1 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2022Q1 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2023Q1 biol Income Tax Provision
IncomeTaxProvision
1000
CY2023Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2022Q1 biol Income Tax Benefit
IncomeTaxBenefit
17000
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.004
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21

Files In Submission

Name View Source Status
0000950170-23-021323-index-headers.html Edgar Link pending
0000950170-23-021323-index.html Edgar Link pending
0000950170-23-021323.txt Edgar Link pending
0000950170-23-021323-xbrl.zip Edgar Link pending
biol-20230331.htm Edgar Link pending
biol-20230331.xsd Edgar Link pending
biol-ex31_1.htm Edgar Link pending
biol-ex31_2.htm Edgar Link pending
biol-ex32_1.htm Edgar Link pending
biol-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
biol-20230331_cal.xml Edgar Link unprocessable
biol-20230331_def.xml Edgar Link unprocessable
biol-20230331_pre.xml Edgar Link unprocessable
biol-20230331_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
biol-20230331_htm.xml Edgar Link completed
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending